Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Shattuck Labs, Inc.STTK · Entity 5224 | Director · Chief Executive Officer | May 12, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Shattuck Labs, Inc.
Report date May 12, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,222 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 25,610 · Balance 122,222 |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 | Direct | 0 |
Reported balance
After 2026-05-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-12 · Exercise / conversion · Disposed 25,610 · Balance 0 F1: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. |
| Common StockSEC Table I · non-derivative | IndirectBy Houghton Capital Holdings, LLC | 2,610,750 |
Reported balance
Holding disclosure · report date 2026-05-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,610,750 |
Filing footnotes · ownership attribution and instrument terms
F1: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.
F2: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 13, 2026 10:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionWarrants (Right to Buy) · Derivative | 25,610 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-26-220506 · ownership.xml · derivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| May 12, 2026 Filed May 13, 2026 10:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 25,610 | $1.08 | $27,776.61 |
DisclosureSEC source: 0001193125-26-220506 · ownership.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,222 Read SEC document |
| January 10, 2026 Filed Jan 13, 2026 21:40 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 1,548,300 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-26-011823 · ownership.xml · derivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,548,300 Underlying: Common Stock · 1,548,300 shares Expires 2036-01-10 F1 · derivative.exercise_date: This option represents the right to purchase a total of 1,548,300 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantWarrants (Right to Buy) · Derivative | 25,610 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001193125-25-189087 · ownership.xml · derivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,610 Underlying: Common Stock · 25,610 shares Expires not disclosed F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F2 · derivative.exercise_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. F2 · derivative.expiration_date: The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 10:30 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantCommon Stock | 25,610 | $0.87 | $22,221.80 |
DisclosureSEC source: 0001193125-25-189087 · ownership.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,612 F1 · kind: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. F1 · price: On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677. Read SEC document |
| January 28, 2025 Filed Jan 28, 2025 22:53 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 684,600 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000950170-25-009987 · ownership.xml · derivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 684,600 Underlying: Common Stock · 684,600 shares Expires 2035-01-28 F1 · derivative.exercise_date: This option represents the right to purchase a total of 684,600 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 10:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | PurchaseCommon Stock | 36,500 | $1.21 | $44,219.75 |
DisclosureSEC source: 0000950170-24-113401 · ownership.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,002 F1 · price: The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.195 to $1.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 26, 2024 Filed Jun 26, 2024 20:15 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | PurchaseCommon Stock | 14,400 | $3.47 | $50,011.20 |
DisclosureSEC source: 0000950170-24-077878 · ownership.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,502 F1 · price: The price reported above is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.413 to $3.499, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 10:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,050 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000950170-24-069059 · ownership.xml · derivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,000 Underlying: Common Stock · 3,050 shares Expires 2033-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents the right to purchase a total of 165,050 shares of the Issuer's common stock and is fully vested. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 10:05 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 3,050 | $3.57 | $10,888.50 |
DisclosureSEC source: 0000950170-24-069059 · ownership.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 21:29 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 330,100 | $0.00 Strike: $9.41 | $0.00 |
DisclosureSEC source: 0000950170-24-004645 · ownership.xml · derivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,100 Underlying: Common Stock · 330,100 shares Expires 2034-01-12 F1 · derivative.exercise_date: This option represents the right to purchase a total of 330,100 shares of the Issuer's common stock, one quarter of which will vest on January 12, 2025, with the remaining three quarters vesting in equal monthly installments through January 12, 2028, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:04 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 165,050 | $0.00 Strike: $3.57 | $0.00 |
DisclosureSEC source: 0000899243-23-002880 · doc4.xml · derivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,050 Underlying: Common Stock · 165,050 shares Expires 2033-01-25 F1 · derivative.exercise_date: This option represents the right to purchase a total of 165,050 shares of the Issuer's common stock, and will vest upon the Issuer's common stock achieving specified share prices during the four years following the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 21:38 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,926 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0000899243-22-003671 · doc4.xml · derivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,597 Underlying: Common Stock · 3,926 shares Expires 2030-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents the right to purchase a total of 188,375 shares of the Issuer's common stock, one quarter of which vested on August 6, 2021, with the remaining three quarters vesting in equal monthly installments through August 6, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 21:38 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 3,926 | $4.67 | $18,334.42 |
DisclosureSEC source: 0000899243-22-003671 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:39 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 178,150 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0000899243-22-001790 · doc4.xml · derivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,150 Underlying: Common Stock · 178,150 shares Expires 2032-01-10 F1 · derivative.exercise_date: This option represents the right to purchase a total of 178,150 shares of the Issuer's common stock, and will vest upon the Issuer's common stock achieving a specified price per share, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 11:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,926 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0000899243-21-044263 · doc4.xml · derivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,523 Underlying: Common Stock · 3,926 shares Expires 2030-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents the right to purchase a total of 188,375 shares of the Issuer's common stock, on quarter of which vested on August 6, 2021, with the remaining three quarters vesting in equal monthly installments through August 6, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 11:10 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 3,926 | $4.67 | $18,334.42 |
DisclosureSEC source: 0000899243-21-044263 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:58 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,926 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0000899243-21-032548 · doc4.xml · derivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,449 Underlying: Common Stock · 3,926 shares Expires 2030-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents the right to purchase a total of 188,375 shares of the Issuer's common stock, one quarter of which vested on August 6, 2021, with the remaining three quarters vesting in equal monthly installments through August 6, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:58 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | Exercise / conversionCommon Stock | 3,926 | $4.67 | $18,334.42 |
DisclosureSEC source: 0000899243-21-032548 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 25, 2021 22:59 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 4,330 | $25.07 | $108,547.90 |
DisclosureSEC source: 0000899243-21-020597 · doc4.xml · nonDerivative · entry 2 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,610,750 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $24.38 to $25.94. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 21, 2021 Filed May 25, 2021 22:59 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 6,215 | $25.56 | $158,844.21 |
DisclosureSEC source: 0000899243-21-020597 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,615,080 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $25.02 to $27.15. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2021 Filed May 21, 2021 00:36 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 7,378 | $26.19 | $193,204.73 |
DisclosureSEC source: 0000899243-21-020286 · doc4.xml · nonDerivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,621,295 F3 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $24.89 to $26.94. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 19, 2021 Filed May 21, 2021 00:36 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 7,794 | $24.63 | $191,963.88 |
DisclosureSEC source: 0000899243-21-020286 · doc4.xml · nonDerivative · entry 2 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,628,673 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $23.835 to $25.29. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 18, 2021 Filed May 21, 2021 00:36 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 4,998 | $26.05 | $130,193.40 |
DisclosureSEC source: 0000899243-21-020286 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,636,467 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $25.085 to $27.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2021 Filed May 18, 2021 01:07 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 6,139 | $26.28 | $161,335.38 |
DisclosureSEC source: 0000899243-21-019686 · doc4.xml · nonDerivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,641,465 F3 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $25.59 to $26.91. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2021 Filed May 18, 2021 01:07 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 11,077 | $26.25 | $290,756.85 |
DisclosureSEC source: 0000899243-21-019686 · doc4.xml · nonDerivative · entry 2 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,647,604 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $25.09 to $27.87. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:07 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 9,856 | $25.91 | $255,401.48 |
DisclosureSEC source: 0000899243-21-019686 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,658,681 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $24.475 to $28.13. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2021 Filed May 13, 2021 00:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 14,242 | $27.29 | $388,637.12 |
DisclosureSEC source: 0000899243-21-019310 · doc4.xml · nonDerivative · entry 3 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,668,537 F3 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $26.335 to $27.89. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2021 Filed May 13, 2021 00:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 14,783 | $28.03 | $414,340.88 |
DisclosureSEC source: 0000899243-21-019310 · doc4.xml · nonDerivative · entry 2 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,682,779 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $25.76 to $28.77. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:35 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | SaleCommon Stock | 8,188 | $26.98 | $220,949.09 |
DisclosureSEC source: 0000899243-21-019310 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Houghton Capital Holdings, LLC Disclosed balance after: 2,697,562 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $26.035 to $29.31. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 21:15 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | GrantStock Option (Right to Buy) · Derivative | 27,563 | $0.00 Strike: $53.02 | $0.00 |
DisclosureSEC source: 0000899243-20-035187 · doc4.xml · derivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,563 Underlying: Common Stock · 27,563 shares Expires 2030-12-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,563 shares of the Issuer's common stock, one quarter of which will vest on December 22, 2021, with the remaining three quarters vesting in equal monthly installments through December 22, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 21:23 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | ConversionSeries B Preferred Stock · Derivative | 397 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028341 · doc4.xml · derivative · entry 5 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,719 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the IPO and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the IPO and had no expiration date. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 21:23 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | ConversionSeries A Preferred Stock · Derivative | 373 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028341 · doc4.xml · derivative · entry 4 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the IPO and had no expiration date. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 21:23 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | ConversionCommon Stock | 2,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-028341 · doc4.xml · nonDerivative · entry 2 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series B Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the IPO and had no expiration date. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 21:23 UTC | Shattuck Labs, Inc. STTK · Entity 5224 | ConversionCommon Stock | 2,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-028341 · doc4.xml · nonDerivative · entry 1 Schreiber Taylor · CIK 0001601942 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into 6.85 shares of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.